2 completed, 1 terminated. 2 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow bebtelovimab: new trials by email Literature Review of bebtelovimab trials Research Report on bebtelovimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness LY3819253, LY3832479, LY3853113 - COVID-19 | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 3307 | 2020-06-17 | 2024-04-11 |
COVID-19 (3)
Eli Lilly and Company (2) · Erin McCreary (1)
United States (3) · Argentina (1) · Puerto Rico (1)
David T Huang, MD, MPH (1) · Erin McCreary, PharmD (1)
PMID 34473343, PMID 35713300, PMID 34374951, PMID 33113295, PMID 33475701, PMID 34034784, PMID 34260849, PMID 34346827, PMID 34718468, PMID 35493124, PMID 35697146, PMID 35834252, PMID 37329415, PMID 38291279, PMID 39230829